...
首页> 外文期刊>Journal of Medicinal Chemistry >Refining the multiple protein structure pharmacophore method: Consistency across three independent HIV-1 protease models
【24h】

Refining the multiple protein structure pharmacophore method: Consistency across three independent HIV-1 protease models

机译:完善多蛋白结构药效团方法:三种独立的HIV-1蛋白酶模型之间的一致性

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Developing methods to incorporate protein flexibility into structure-based drug design is an important challenge. Our approach uses multiple protein structures ( MPS) to create a receptor-based pharmacophore model of the desired target. We have previously demonstrated the success of the method by applying it to human immunodeficiency virus-1 protease ( HIV-1p). Our models, based on an apo structure, discriminated known HIV-1p inhibitors from druglike inactive compounds and also accurately identified bound conformations of known inhibitors. Here, we test the method by applying it to all three unbound crystal structures of HIV-1p. We have also improved our method with denser probe mapping of the binding site and refined our selection criteria for pharmacophore elements. Our improved protocol has led to the development of a consistent 8-site pharmacophore model for HIV-1p, which is independent of starting structure, and a robust MPS pharmacophore method that is more amenable to automation.
机译:开发将蛋白质柔韧性纳入基于结构的药物设计的方法是一项重要的挑战。我们的方法使用多种蛋白质结构(MPS)创建所需靶标的基于受体的药效团模型。我们以前通过将其应用于人类免疫缺陷病毒1蛋白酶(HIV-1p)证明了该方法的成功。我们基于载脂蛋白结构的模型将已知的HIV-1p抑制剂与药物样非活性化合物区分开,并准确鉴定了已知抑制剂的结合构象。在这里,我们通过将其应用于HIV-1p的所有三个未绑定晶体结构来测试该方法。我们还通过更密集的结合位点探针图谱改进了我们的方法,并完善了药效基团元素的选择标准。我们改进的方案已导致开发了针对HIV-1p的一致的8位药效基团模型,该模型独立于起始结构,并且开发了一种更适合自动化的可靠的MPS药效基团方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号